Friday, January 24, 2014

The Motley Fool: Covidien plc. Delivers Yet Again

About two weeks ago, I wondered whether the Street had caught up to Covidien (NYSE: COV  ) . Apparently the answer is "no", as the company once again beat expectations with strong sales growth and particularly strong performance in its core surgical business.

I still don't think Covidien is particularly cheap, but that's a complaint I make a lot these days in the health care sector. On a relative basis, I think Covidien, Johnson & Johnson (NYSE: JNJ  ) , and Stryker (NYSE: SYK  ) are above-average calls on a relative basis, as they're exposed to improving procedural growth across multiple markets.

Follow this link for more:
Covidien plc. Delivers Yet Again

No comments: